FDA halts trial of BioNTech-MediLink ADC over 'significant risk of illness'

The FDA has slammed the brakes on a trial of MediLink Therapeutics’ BioNTech-partnered antibody-drug conjugate (ADC) that has already seen three fatalities, with the agency citing a risk of “unreasonable and significant risk of illness or injuries.”